Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress
Eli Lilly's strong Q2 2026 results and raised guidance are driving business news, contrasting with The Trade Desk's earnings miss
Evidence dossier
Intelligence passport
Measured timeline
- Detected The first matching coverage entered the Archynetys cluster.
- Latest coverage observed Most recent article currently attached to this story cluster.
- Peak measured velocity The recorded velocity reached 22.
- Evidence threshold reached The story had enough independent coverage for an explanatory brief.
Source diversity sample: Ad Age · marketwatch.com · Seeking Alpha · benzinga.com · investors.thetradedesk.com · Financial Times · Reuters · qz.com.
How this dossier is built: methodology · AI policy · corrections.
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Where it stands
Eli Lilly and The Trade Desk both released their second-quarter 2026 financial results. The company missed revenue expectations and issued a weak outlook. Lilly's results beat expectations. The company raised its full-year revenue forecast. Lilly's growth is driven by continued demand for its GLP-1 drugs.
Lilly's results were reported by Reuters, the Financial Times, the Wall Street Journal, and QZ. The Trade Desk's results were reported by Ad Age, MarketWatch, Seeking Alpha, and Benzinga. The Trade Desk's report came after it had repaired rifts with agencies. The company's revenue growth had stalled. The Trade Desk's shares cratered on the news.
Lilly's results come amid a surge in demand for weight-loss drugs. The company's pipeline progress is also noted. Lilly's raised guidance reflects continued growth. The Trade Desk's weak outlook suggests challenges ahead. The contrast between the two companies' performances is driving business news.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (88% supported) Updated 1h ago.
Coverage (9)
- The Trade Desk’s revenue growth stalls even as it repairs agency rifts Ad Age · 4h ago
- Trade Desk shares tumble on earnings miss and weak outlook marketwatch.com · 4h ago
- Trade Desk sinks on revenue miss, margin pressure (TTD:NASDAQ) Seeking Alpha · 4h ago
- The Trade Desk Stock Craters on Q2 Earnings benzinga.com · 4h ago
- The Trade Desk Reports Second Quarter 2026 Financial Results investors.thetradedesk.com · 4h ago
- Eli Lilly and Novo Nordisk raise profit outlook as demand for weight-loss drugs soars Financial Times · 1d ago
- Eli Lilly raises annual revenue forecast as GLP-1 drugs fuel growth Reuters · 1d ago
- Eli Lilly Q2 2026 earnings beat, raises full-year revenue forecast qz.com · 1d ago
- Eli Lilly Posts Higher Revenue on Continued GLP-1 Demand WSJ · 1d ago
Answered
What drove Eli Lilly's Q2 2026 growth?
Eli Lilly's Q2 2026 growth was driven by continued demand for its GLP-1 drugs.
Why did The Trade Desk's shares tumble?
The Trade Desk's shares tumbled due to a revenue miss and weak outlook.
What is the current demand for weight-loss drugs?
Demand for weight-loss drugs is soaring, according to the Financial Times.
Topics
Related trends
Amazon to Offer GLP-1 Weight-Loss Drugs to Medicare Part D Patients
Amazon, CVS and Walmart are racing to deliver GLP-1 weight-loss drugs to Medicare patients.
How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?
Novo Nordisk faces intensifying competition from Lilly as the weight-loss drug market shifts and the search for a new blockbuster intensifies.
CVS Stock Slides On 2027 Outlook Despite Hearty Earnings Beat
CVS Health's stock is falling despite a strong earnings report, due to a cautious outlook for 2027.
GLP-1 Drugs May Have a Hidden Effect on Your Eyes, Study Finds
A study links popular GLP-1 drugs to vision loss, sparking concern among patients and optometrists.
‘Temporal wasting’: The GLP-1 side effect that makes patients ‘look suddenly older’
A side effect of popular weight-loss drugs is causing patients to appear older.
Novo Nordisk Stock Stumbles On A Key Miss As Its Battle With Eli Lilly Heats Up
Novo Nordisk's stock price drops despite beating earnings forecasts, as investors react to revised guidance.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.